PFE
Pfizer’s got a little swagger back
Pfizer opened the earnings buffet and came back for seconds. The drugmaker said it delivered a strong second quarter of 2026 and lifted the midpoint of its full-year revenue guidance by $500 million. In plain English: management is seeing a little more business than it expected, and that’s usually a nice smell coming from a pharma company’s kitchen.
The headline isn’t just the beat — it’s the guide
Revenue guidance is the number investors usually squint at first because it tells you what management thinks the rest of the year looks like. Raising the midpoint suggests Pfizer sees enough momentum to get a bit more optimistic without doing victory laps in the hallway.
A few things to note:
- Pfizer reaffirmed its adjusted diluted EPS guidance.
- That EPS outlook still absorbs about a $0.10 impact from the Innovent Biologics, Inc. transaction.
- So yes, the company is still dealing with some transaction-related noise, but it’s managing to keep the core story intact.
Why investors should care
This is less about one flashy quarter and more about whether Pfizer is stabilizing after a pretty noisy stretch for big pharma names. If revenue is trending better and the company can hold the line on earnings guidance despite acquisition-related drag, that gives bulls something to point to besides a hope-and-a-prayer slide deck.
Big picture: Pfizer doesn’t need to become the cool kid of the market overnight. It just needs to keep proving that its cash machine still works, and this update says the machine is at least humming, not wheezing.